Get the Stockscreener App
1.98
4.35%
-0.09
After Hours:
1.98
Cardiol Therapeutics Inc stock is traded at $1.98, with a volume of 350.35K.
It is down -4.35% in the last 24 hours and up +2.06% over the past month.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
See More
Previous Close:
$2.07
Open:
$2.03
24h Volume:
350.35K
Relative Volume:
1.19
Market Cap:
$138.37M
Revenue:
-
Net Income/Loss:
$-20.75M
P/E Ratio:
-5.6394
EPS:
-0.3511
Net Cash Flow:
$-23.71M
1W Performance:
-13.91%
1M Performance:
+2.06%
6M Performance:
+9.39%
1Y Performance:
+121.23%
1-Day Range:
$1.96
$2.0688
1-Week Range:
$1.96
$2.42
52-Week Range:
$0.661
$3.12
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Cardiol Therapeutics Inc Stock (CRDL) Latest News
Pericarditis Drugs Market to Boost Revenue Potential, - openPR
Cardiol Therapeutics (OTCMKTS:CRTPF) Shares Down 3.6% - Defense World
Cardiol Therapeutics (TSE:CRDL) Shares Up 1.1% - MarketBeat
Cardiol Therapeutics (TSE:CRDL) Trading Up 1.1% - Defense World
Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis - Investing News Network
Cardiol Therapeutics reaches target enrollment for Phase II acute myocarditis trial - Proactive Investors UK
Cardiol Therapeutics’ Landmark Enrollment for Heart Drug Trial - TipRanks
Cirion debuts voice and collaboration service in Chile - Telecompaper EN
Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis - StockTitan
Guardion Health Sciences announces executive shake-up - Investing.com India
Returns On Capital At Churchill Downs (NASDAQ:CHDN) Have Stalled - Simply Wall St
Corebridge Financial, Inc. (NYSE:CRBG) Shares Acquired by Hsbc Holdings PLC - Defense World
Federated Hermes Inc. Trims Holdings in Churchill Downs Incorporated (NASDAQ:CHDN) - Defense World
Cuprina Holdings (Cayman) Ltd Plans $16 Million IPO for September 27th (CUPR) - Defense World
Deep Dive Into Capricor Therapeutics Stock: Analyst Perspectives (5 Ratings) - Benzinga
Renaissance Technologies LLC Decreases Position in Church & Dwight Co., Inc. (NYSE:CHD) - Defense World
Cibus Shares Fall on Plan to Raise $12 Million in Offering - MarketWatch
Cannabinoid Derived Pharmaceutical Market Vendor and Technology Assessment Report 2024-2031 - WhaTech
Research Analysts Issue Forecasts for Cardiol Therapeutics Inc.’s Q3 2024 Earnings (NASDAQ:CRDL) - Defense World
Q3 2024 EPS Estimates for Cardiol Therapeutics Inc. (NASDAQ:CRDL) Lifted by Analyst - MarketBeat
Cardiol Therapeutics (CRDL) Upgraded to Buy: Here's Why - Yahoo Finance
Healthy Upside Potential: Cardiol Therapeutics Inc (CRDL) - SETE News
The Globe and Mail - The Globe and Mail
“Cardiol Therapeutics (NASDAQ: CRDL) Myocarditis Breakthrough Featured on Fox Business: CardiolRx™ Poised for Medical Impact more stocks inside…” - Barchart
Inside the production pipeline for new drugs to combat heart failure - Fox Business
Cardiol Therapeutics Inc (CRDL) Stock: Navigating a Year of Volatility - The InvestChronicle
Cardiol Therapeutics Inc (CRDL) deserves closer scrutiny - US Post News
Cardinal Energy Ltd. - Baystreet.ca
Cardiol Therapeutics Inc - Baystreet.ca
Cardiol Therapeutics to unveil data from Phase 2 recurrent pericarditis study - Proactive Investors UK
Cardiol Therapeutics to present Phase II study results - Investing.com
Cardiol Therapeutics Advances Heart Disease Treatment - TipRanks
Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024 - Newsfile
Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024 - StockTitan
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
The Realreal Inc (REAL-Q) QuotePress Release - The Globe and Mail
Cardiol Therapeutics Inc (CRDL) Shares Up 8.74% on Sep 9 - GuruFocus.com
Foundations Investment Advisors LLC Buys New Position in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Receives $8.75 Consensus Price Target from Analysts - MarketBeat
GAP (NYSE:GPS) & ABC-Mart,Inc. (OTCMKTS:AMKYF) Head-To-Head Survey - Defense World
1 Copper Stock to Buy at a Discount This September - The Globe and Mail
Cardiol Therapeutics (NASDAQ:CRDL) Shares Down 4.2% - Defense World
Cardiol Therapeutics (NASDAQ:CRDL) Trading Down 4.2% - MarketBeat
RBOB Blendstock (LGF24) Quote - The Globe and Mail
Gold’s Quick Reversal and Copper’s Major Indications - The Globe and Mail
Docusign Inc (DOCU-Q) QuotePress Release - The Globe and Mail
Cardiol Therapeutics (TSE:CRDL) Stock Price Up 0.8% - Defense World
Cardiol Therapeutics (TSE:CRDL) Trading 0.8% Higher - MarketBeat
Cardiol Therapeutics (OTCMKTS:CRTPF) Stock Price Down 2.1% - Defense World
S&P 500 Industrials [Sector] (SRIN) QuotePress Release - The Globe and Mail
Raymond James Trust N.A. Has $900,000 Holdings in BlackRock Health Sciences Trust (NYSE:BME) - Defense World
Cardiol Therapeutics Inc Stock (CRDL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.23%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):